Yasir Y Elamin, MD
M.D. Anderson Cancer Center · MD Anderson Cancer Cetner
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yasir Y Elamin, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07415005 · Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerM.D. Anderson Cancer Center · recruiting · Advanced Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT06522360 · Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)M.D. Anderson Cancer Center · withdrawn · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT04837716 · Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerM.D. Anderson Cancer Center · active not recruiting · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 · principal investigator
- Ph1NCT04479306 · Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerM.D. Anderson Cancer Center · completed · Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph1NCT03707938 · Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerM.D. Anderson Cancer Center · active not recruiting · Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.